Congratulations to Axonis Therapeutics on this milestone. We are honored that our small grant to the company over a year ago earned us a mention in this press release. And hopeful, that this incredible team will find a way to use their molecule for the benefit of the #SYNGAP1 community.
Proud of the Axonis Therapeutics #team for this significant financial milestone in our mission to develop first-in-class oral #KCC2 #neuromedicines to address unmet needs of neurological disorder patients! Our $115M Series A brought together a high caliber syndicate of investors who share our vision and will greatly enable and guide us to progress through proof-of-concept clinical trials, which also speaks to the quality of the #science, #drug candidates and relentless efforts of the global team of Axoneers. We are also eternally grateful to the investors, funding agencies and foundations who supported us over the last 5 years. Axonis are truly standing on the shoulders of giants in the KCC2 field, particularly Prof. Yves De Koninck at Université Laval and Prof. Zhigang He at Boston Children's Hospital and Harvard Medical School from which the #biotech company was spun out. With first-in-human clinical trials starting in December, we are a step further to executing on Dr. Joanna Stanicka’s and Prof. Corey Goodman’s (venBio) vision and mission for Axonis, whose passion, perseverance and expertise have driven us to these milestones. Immense credit also to patient advocate Bob Yant who first launched this journey to make impactful medicines that improve patients lives. https://lnkd.in/e6pHcWZm